Fate Therapeutics has appointed Jamie Harrell as Senior Vice President of Market Development & Commercial Operations to spearhead the commercialization of its CAR T-cell therapies, including FT819 and FT839, targeting autoimmune diseases like lupus nephritis and rheumatoid arthritis. Harrell brings over 25 years of commercial leadership, with experience launching breakthrough autoimmune treatments and expanding access through outpatient settings. His role will focus on advancing Fate's therapies from clinical trials to market, aiming to broaden patient access in community healthcare settings. This strategic hire supports Fate's goal to transform autoimmune disease treatment with innovative, off-the-shelf cellular immunotherapies.
Fate Therapeutics' strategic leadership update coincides with a mixed performance among health-sector stocks on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 12, 2026 18:11 WIB: out of 128 priced health-sector US stocks, 60 rose and 45 fell. Notable movers include ABCL (AbCellera Biologics Inc) up 1.55% at USD 12.74, NVAX (Novavax Inc) down 1.80% at USD 12.52, and CTXR (Citius Pharmaceuticals Inc) down 1.86% at USD 0.49, with typical hold times ranging from 17 to 59 days on Pluang.
Harmony Biosciences announced that Peter Anastasiou will become President and CEO effective January 1, 2027, succeeding Jeffrey M. Dayno, who will retire at the end of 2026. Dayno will remain as a non-executive advisor through 2027 to support the com...
Zenas BioPharma presented new data on obexelimab at the 6th International Symposium on IgG4-Related Disease, highlighting sustained clinical activity in treating IgG4-RD. Phase 3 INDIGO open-label extension results showed a high probability of patien...
The St. Louis Blues and Gray Media announced a multi-year deal to broadcast 10 select Thursday games over-the-air on ABC 32 in St. Louis and 10 other markets during the 2026-27 NHL season. This expands access to Blues games for over 4.8 million house...
Iridex Corporation announced a two-year clinical study demonstrating that MicroPulse transscleral laser therapy significantly reduces intraocular pressure (IOP) and medication use in patients with early to advanced glaucoma. The study, involving 84 e...
The European Commission has chosen Neo Performance Materials' Silmet 2.0 as one of 46 Strategic Projects under the EU's Critical Raw Materials Act, recognizing its importance in rare earth processing. Greenland Mines, a key shareholder in Neo, sees t...
